基于管腔型非编码RNA的基因组分类器证实临床器官局限性膀胱癌根治性膀胱切除术后患者预后良好
本研究对226例接受根治性膀胱切除术且未行新辅助治疗的高级别临床器官局限性(cTa-T2N0M0)尿路上皮癌患者的经尿道膀胱肿瘤切除标本进行转录组表达谱分析,以验证基于长链非编码RNA的基因组分类器。结果显示60例为管腔型预后良好亚型,该亚型与较低的病理分期升级几率和更好的总生存显著相关。
要点
- 管腔型预后良好亚型与较低的病理T3+期升级几率显著相关(OR 0.32,95%CI 0.12-0.82;P=0.02)。
- 管腔型预后良好亚型与更好的总生存显著相关(HR 0.33,95%CI 0.15-0.74;P=0.007)。
- 该基因组分类器可识别生物学侵袭性较低的尿路上皮癌亚型。
核心结论
- 本研究验证了基因组分类器识别管腔型预后良好亚型尿路上皮癌的性能,该亚型具有较低侵袭性的肿瘤生物学特征。
研究设计与样本
- 对226例高级别、临床器官局限性(cTa-T2N0M0)尿路上皮癌患者的经尿道膀胱肿瘤切除标本进行转录组表达谱分析,这些患者随后接受根治性膀胱切除术且未行新辅助治疗。
- 使用先前开发的基因组分类器判定基于长链非编码RNA的管腔型预后良好状态,主要终点为根治性膀胱切除术后总生存。
主要发现
- 研究中134例为临床非肌层浸润性膀胱癌(cTa/Tis/T1),92例为cT2。
- 共识别出60例管腔型预后良好亚型患者,均显示与较低侵袭性膀胱癌生物学相关的稳健基因表达模式。
- 多变量分析显示,管腔型预后良好亚型(相比无该亚型)与较低的病理(p)T3+期疾病升级几率显著相关(OR 0.32,95%CI 0.12-0.82;P=0.02)。
- 管腔型预后良好亚型与较低的任意升级几率显著相关(OR 0.41,95%CI 0.20-0.83;P=0.01)。
- 管腔型预后良好亚型与较低的任意升级和/或pN+几率相关(OR 0.50,95%CI 0.25-1.00;P=0.05)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To further evaluate a genomic classifier (GC) in a cohort of patients undergoing radical cystectomy (RC), as long non-coding RNA (lncRNA)-based genomic profiling has suggested utility in identifying a distinct tumour subgroup corresponding to a favourable prognosis in patients with bladder cancer. PATIENTS AND METHODS: Transcriptome-wide expression profiling using Decipher Bladder was performed on transurethral resection of bladder tumour samples from a cohort of patients with high-grade, clinically organ-confined (cTa-T2N0M0) urothelial carcinoma (UC) who subsequently underwent RC without any neoadjuvant therapy (n = 226). The lncRNA-based luminal favourable status was determined using a previously developed GC. The primary endpoint was overall survival (OS) after RC. Secondary endpoints included cancer-specific mortality and upstaging at RC. RESULTS: In the study, 134 patients were clinical non-muscle-invasive bladder cancer (cTa/Tis/T1) and 92 patients were cT2. We identified 60 patients with luminal favourable subtype, all of which showed robust gene expression patterns associated with less aggressive bladder cancer biology. On multivariate analysis, patients with the luminal favourable subtype (vs without) were significantly associated with lower odds of upstaging to pathological (p)T3+ disease (odds ratio [OR] 0.32, 95% confidence interval [CI] 0.12-0.82; P = 0.02), any upstaging (OR 0.41, 95% CI 0.20-0.83; P = 0.01), and any upstaging and/or pN+ (OR 0.50, 95% CI 0.25-1.00; P = 0.05). Luminal favourable bladder cancer was significantly associated with better OS (hazard ratio 0.33, 95% CI 0.15-0.74; P = 0.007). CONCLUSIONS: This study validates the performance of the GC for identifying UCs with a luminal favourable subtype, harbouring less aggressive tumour biology.
引用
- de Jong JJ, Proudfoot JA, Daneshmand S, et al. A luminal non-coding RNA-based genomic classifier confirms favourable outcomes in patients with clinically organ-confined bladder cancer treated with radical cystectomy. BJU Int. 2024. PMID: 39485082. doi:10.1111/bju.16572
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。